NEW YORK, Feb. 21, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. (“Regulus”) (NASDAQ:RGLS) between February 17, 2016 and January 27, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Jin v. Regulus Therapeutics Inc., et al. (Case No. 17cv0267 LAB JMA) in the USDC for the Southern District of California. To get more information go to:
http://www.zlk.com/pslra/regulus-therapeutics
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Regulus made materially false and/or misleading statements and/or failed to disclose that: (i) RG-101 was not safe and well tolerated by all patients in the ongoing studies, (ii) cases of serious adverse events (“SAE”) were discovered, (iii) the SAEs were proof of serious concerns about the safety profile of RG-101, (iv) Regulus would likely need to produce extensive data to the U.S. Food and Drug Administration (“FDA”) to continue clinical trials of RG-101, and (v) as a result of the foregoing, Defendants’ statements about Regulus’ business and prospects were false and misleading and/or lacked a reasonable basis.
Take Action: if you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Anta Sports Expands Global Footprint With Strategic Puma Stake
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



